Responses
Drug information (i. anti-infectives, ii. cytostatics, iii. others)
DGI-018 Budget Impact Analysis on New 3-Year Imatinib Adjuvant Treatment For Patients with Operable GIST at High Risk of Recurrence
Compose a Response to This Article
Other responses
No responses have been published for this article.